RxDoctor Payments Data

David Tetrokalashvili, DPM

Podiatrist · Brooklyn, NYNPI 1518988021

Payments from drug & device makers

$639in general payments, 2019–2025

Across 35 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$370
  • Sumitomo Pharma America, Inc.$46
  • Rhythm Pharmaceuticals, Inc.$36
  • Ascendis Pharma Endocrinology Inc$23
  • Sebela Pharmaceuticals Inc.$22
  • Tandem Diabetes Care, Inc.$22
  • plus $120 from 6 others

What the payments were for

  • Food & beverage$639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$639 in reported general payments places this provider in the 50th percentile of 862 podiatrist providers in New York.

See all podiatrist providers in New York

Medicare billing

Part B allowed, 2024
$703,555
Medicare patients
825
Services billed
10,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole1,735$2,417,135
Diclofenac Sodium1,218$1,227,802
VtamaTapinarof338$460,727
Oxiconazole Nitrate763$413,681
EnstilarCalcipotriene/Betamethasone149$372,721
ZipsorDiclofenac Potassium123$212,623
ErtaczoSertaconazole Nitrate141$188,182
Diflorasone Diacetate226$166,764
Diclofenac Potassium114$134,459
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag117$97,080
OpzeluraRuxolitinib Phosphate50$94,774
NoritateMetronidazole35$61,405
NaftinNaftifine Hcl94$43,028
Amcinonide20$34,349
LicartDiclofenac Epolamine25$32,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dermavant Sciences, Inc.Vtama$21$460,727338 claims
Assertio Therapeutics, Inc.Zipsor$18$212,623123 claims
Incyte CorporationOpzelura$21$94,77450 claims
Sebela Pharmaceuticals Inc.Naftin$22$43,02894 claims
IBSA Pharma Inc.Licart$19$32,34625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 862 podiatrist providers in New York.

Other podiatrist in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →